Quick Answer
Spyre Therapeutics, Inc. reported Net Income of -$155.20 million for fiscal year 2025.
Spyre Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$155.20M | +25.4% |
| 2024 | -$208.02M | +38.6% |
| 2023 | -$338.79M | -304.2% |
| 2022 | -$83.81M | -27.4% |
| 2021 | -$65.80M | +18.7% |
| 2020 | -$80.89M | -3.4% |
| 2019 | -$78.25M | -76.5% |
| 2018 | -$44.35M | -62.8% |
| 2017 | -$27.24M | -25.5% |
| 2016 | -$21.70M | -92.1% |
| 2015 | -$11.29M | -9.2% |
| 2014 | -$10.35M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$11.18M | +83.8% | +69.5% |
| June 30, 2025 | -$36.72M | +5.5% | +18.0% |
| March 31, 2025 | -$44.77M | -2.1% | +35.1% |
| September 30, 2024 | -$69.03M | -72.1% | -77.7% |
| June 30, 2024 | -$38.84M | +82.1% | +11.4% |
| March 31, 2024 | -$43.86M | -138.1% | -9.3% |
| September 30, 2023 | -$40.11M | -120.0% | +81.5% |
| June 30, 2023 | -$217.08M | -872.5% | -1078.4% |
- Spyre Therapeutics, Inc. showed an increase of +25.4% in Net Income compared to the prior fiscal year.
- Over the 2014–2025 period, Spyre Therapeutics, Inc.’s net income has declined by 1400.0% (from -$10.35 million to -$155.20 million).
- The most recent figure is from Spyre Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: